Mr. Haines has more than 25 years of international management experience in the life sciences industry in both public and private companies. During his time at Abingworth, Mr. Haines has taken board roles in a number of companies including Astex, Fovea, GammaDelta Therapeutics, MEDIAN Technologies, PowderMed, Sientra, Virion, Scorpion, Venatorx Pharmaceuticals and Adaptate Biotherapeutics. Before joining Abingworth in 2005, Mr. Haines was Chief Executive of the Abingworth portfolio company, Astex Therapeutics. He was with Astex for over five years and was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, Mr. Haines was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the US and Europe, including CEO of Thackray Inc and General Manager Baxter UK. Mr. Haines has a BSc from Exeter University and an MBA from INSEAD. He is a former Director of the BIA and sat on the BVCA Venture Committee and the Wellcome Trust / NHS Health Innovation Challenge Fund.

Carly Levine, PhD, is an Associate at the AMR Action Fund (AMRAF), where she is responsible for evaluating innovative technologies, cultivating investment opportunities, and supporting the fund’s portfolio companies across a wide range of initiatives. She joined AMRAF as an Analyst in November 2021 and has since guided numerous investments into clinical-stage biotechnology companies that are developing therapeutics or diagnostics for high-priority drug-resistant pathogens. Prior to joining AMRAF, she spent nearly a decade in academia, where she developed a deep understanding of the biology of drug resistance and the science that underpins novel antimicrobial development. She holds a PhD in microbiology and an MS in biomedical sciences from Rutgers University. She currently serves on the boards of BioVersys, Pattern Bioscience, and Venatorx Pharmaceuticals and has served on the boards of Antabio and Adaptive Phage Therapeutics.

Dr. Perros is a pharmaceutical and biotech executive with over 30 years of experience in life sciences R&D. He began his career as a chemist and conducted his Ph.D. work in Belgium, France, and Germany, before joining the Biophysics department at Yale as an Associate from 1993 to 1995.

Between 2015 and 2022, Manos Perros was Chief Executive Officer of Entasis Therapeutics, where he played a pivotal role in establishing the company as a prominent player in the industry, resulting in the acquisition of the company by Innoviva in 2022 and the FDA approval of Xacduro, the first targeted treatment for Acinetobacter baumannii pneumonia, in 2023. More recently, Dr. Perros was President and Chief Executive Officer of Hillstar Bio, a precision immunology company developing treatments for patients with autoimmune diseases.

Before founding Entasis, Dr. Perros held the positions of Vice President and Head of AstraZeneca’s Infection Research and Early Development organization and Site Head for AstraZeneca’s Boston R&D research center. Prior to that, Dr. Perros was the Director of the Novartis Institute for Tropical Diseases in Singapore, and Vice-President and Chief Scientific Officer, Antivirals, at Pfizer, where he led the R&D program which culminated in the approval of Selzentry, a first-in-class treatment for HIV. While at Pfizer, he also directed research in a variety of therapeutic areas including Obesity, Pain, and Urology.

Throughout his illustrious career, Dr. Perros has successfully led numerous organizations through various stages of growth and development, earning him a reputation as a visionary leader in the industry. Manos Perros has made substantial contributions to the field of anti-infectives, and is widely recognized and published as a distinguished scientist, having led research projects against HIV, Hepatitis C, influenza, as well as bacterial and fungal pathogens. Dr. Perros is also Chairman of the Board of Aurobac Therapeutics, and serves as Independent Director at Riva Therapeutics as well as Chairman of the Scientific Advisory Board of the GHDDI (Beijing).

Henry Skinner, PhD, MJur, is Chief Executive Officer at the AMR Action Fund. Prior to joining the fund, he held leadership positions across the pharmaceutical and venture capital sectors, including serving as Senior Vice President, Venture at Tekla Capital Management and as Deputy Head and Managing Director of the Novartis Venture Fund. In addition, Henry was the CEO of SelectX Pharmaceuticals, which focused on developing small-molecule antimicrobials, and NeoGenesis Pharmaceuticals, which developed a platform for identifying and optimizing drug candidates.

Over the years, he has held Business Development positions at the Novartis Institutes for Biomedical Research, Pfizer, Pharmacia, Pharmacia & Upjohn, and Lexicon Genetics. Henry was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics. He earned a PhD in Microbiology and an MS in Biochemistry from the University of Illinois; an MJur in Health Law, Policy, and Management from Texas A&M; and an MS and a BS in Biology/Biotechnology from Worcester Polytechnic Institute.